SOP Guide for Pharma

Analytical Method Development: GC Headspace Method Optimization – V 2.0

Analytical Method Development: GC Headspace Method Optimization – V 2.0

SOP for Optimization of GC Headspace Method for Residual Solvent Analysis


Department Analytical Method Development
SOP No. SOP/AMD/085/2025
Supersedes SOP/AMD/085/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the standard procedure for the optimization of GC Headspace methods for estimation of residual solvents in pharmaceutical raw materials and finished products. The aim

is to ensure accurate, precise, and reproducible analysis as per ICH Q3C and regulatory requirements.

2. Scope

This procedure applies to all gas chromatography methods using headspace injection mode within the Analytical Method Development (AMD) laboratory for the analysis of volatile residual solvents in drug substances and drug products.

3. Responsibilities

  • Analytical Chemist: Conducts headspace parameter optimization, evaluates sensitivity, and performs method robustness trials.
  • Method Reviewer: Verifies optimization studies and ensures method consistency across matrices.
  • QA Officer: Ensures compliance with GMP and records verification.
  • Head – AMD: Reviews and approves the optimized method for validation and regulatory use.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that the optimized headspace method meets all system suitability and regulatory criteria for residual solvent testing.

5. Procedure

5.1 Pre-Optimization Setup

  1. Review solvent class and boiling point characteristics from ICH Q3C.
  2. Choose headspace-compatible solvents such as acetone, methanol, ethanol, IPA, etc.
  3. Document solvents and their regulatory limits in Annexure-1: Solvent Screening Sheet.

5.2 Instrument Configuration

  1. Instrument: GC with Headspace Sampler and FID.
  2. Headspace vial: 20 mL, crimp cap with PTFE/silicone septum.
  3. Column: DB-624 (30 m × 0.32 mm × 1.8 µm).
  4. Carrier gas: Helium or nitrogen, constant flow at 1.0 mL/min.
  5. Record instrument parameters in Annexure-2: Instrument Configuration Log.

5.3 Headspace Conditions Optimization

  1. Test various conditions to identify optimal parameters:
    • Incubation Temperature: 70°C, 80°C, 90°C
    • Incubation Time: 15, 20, 30 minutes
    • Injection Volume: 1.0 mL
    • Shaking speed: Low, Medium, High (if applicable)
  2. Evaluate peak area response, reproducibility, and baseline noise.
  3. Document observations in Annexure-3: Headspace Optimization Log.

5.4 Sample and Standard Preparation

  1. Standard: Prepare individual and mixed stock solutions in DMSO or DMF at concentrations near ICH limits.
  2. Sample: Weigh 300–500 mg of sample into headspace vial and add 5 mL of diluent.
  3. Seal vial using crimper and vortex if needed.
  4. Log preparation details in Annexure-4: Sample & Standard Prep Log.

5.5 Method Evaluation and Specificity

  1. Inject:
    • Blank diluent
    • Placebo
    • Standard mixture
    • Sample
  2. Overlay chromatograms and check for:
    • Peak purity
    • No interference near target solvent retention times
  3. Document in Annexure-5: Specificity Evaluation Report.

5.6 System Suitability and Linearity

  1. Prepare linearity solutions at 50%, 80%, 100%, 120%, 150% levels.
  2. Inject in duplicate and construct calibration curve.
  3. System suitability parameters:
    • RSD ≤ 5% for replicate injections
    • Resolution ≥ 1.5 between nearest solvent peaks
  4. Log in Annexure-6: System Suitability and Linearity Report.

5.7 Robustness and Matrix Effect

  1. Test matrix effects using spiked placebo and actual samples.
  2. Evaluate changes in:
    • Peak area
    • RT shift
    • Co-elution
  3. Adjust headspace temperature or ramp rate if needed.
  4. Record findings in Annexure-7: Matrix Effect and Robustness Log.

6. Abbreviations

  • GC: Gas Chromatography
  • FID: Flame Ionization Detector
  • RT: Retention Time
  • ICH: International Council for Harmonisation
  • RSD: Relative Standard Deviation
  • SOP: Standard Operating Procedure

7. Documents

  1. Solvent Screening Sheet – Annexure-1
  2. Instrument Configuration Log – Annexure-2
  3. Headspace Optimization Log – Annexure-3
  4. Sample & Standard Prep Log – Annexure-4
  5. Specificity Evaluation Report – Annexure-5
  6. System Suitability and Linearity Report – Annexure-6
  7. Matrix Effect and Robustness Log – Annexure-7

8. References

  • ICH Q3C(R8) – Residual Solvents
  • ICH Q2(R1) – Validation of Analytical Procedures
  • USP <467> – Residual Solvents
  • USP <621> – Chromatography

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Solvent Screening Sheet

Solvent Class Boiling Point (°C) ICH Limit (ppm)
Acetone Class 3 56.2 5000
Methanol Class 2 64.7 3000

Annexure-2: Instrument Configuration Log

Instrument Detector Column Carrier Gas Injector Temp
Agilent 8890 FID DB-624 Helium 200°C

Annexure-3: Headspace Optimization Log

Parameter Value Observation Finalized
Incubation Temp 80°C Good peak response Yes
Incubation Time 20 min Stable baseline Yes

Annexure-4: Sample & Standard Prep Log

ID Type Solvent Conc. (ppm) Diluent
STD-001 Standard Methanol 3000 DMSO

Annexure-5: Specificity Evaluation Report

Injection Peak Interference RT Overlap Status
Placebo No No Complies

Annexure-6: System Suitability and Linearity Report

Parameter Value Limit Status
RSD 1.8% ≤5% Pass
0.9993 ≥0.995 Pass

Annexure-7: Matrix Effect and Robustness Log

Condition Observation Peak Area Deviation Status
Placebo Spiked No co-elution +1.2% Acceptable

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added matrix robustness and specificity annexures Annual Update
Exit mobile version